GLP-1 Medications and Hidradenitis Suppurativa: Inflammation, Obesity, and Emerging Evidence

Q: Can GLP-1 replace biologic therapy for HS?

No — GLP-1 medications should not replace established HS-specific treatments. Current standard of care for moderate-to-severe HS: adalimumab (Humira, FDA-approved for HS), secukinumab (FDA-approved for HS 2023), bimekizumab (approved 2024), antibiotics (clindamycin + rifampicin), and surgical drainage/excision. GLP-1's role in HS is as an adjunct that addresses the underlying metabolic driver — obesity — rather than a direct anti-inflammatory targeting HS-specific pathways. In clinical practice, obese HS patients may experience meaningful disease improvement as a secondary benefit of GLP-1 treatment initiated for obesity or metabolic indications. Dermatologists managing HS in obese patients should be aware of this effect.

Q: How long does it take for GLP-1 to improve HS?

Based on case reports and series, HS improvement with GLP-1 appears to follow the trajectory of weight loss: initial improvement in lesion frequency and severity typically observed after 10–15% weight loss (often months 3–6 of treatment); more significant improvement after 15–20% loss (months 6–12); most improvement is seen at stable goal weight (12+ months). HS is not an acute condition — improvement is gradual and correlates with sustained metabolic change rather than any direct drug effect. Patients should not expect immediate HS improvement at the start of GLP-1 treatment. Realistic timeline: 3–6 months for initial improvement signals; 12+ months for meaningful disease modification.

Can GLP-1 medications help hidradenitis suppurativa? The obesity-inflammation link, emerging evidence for GLP-1 in HS, and what to expect. April 2026.

Sarah ChenLead Health Editor

Updated April 15, 2026

5 questions

Quick Answers

Click any question to expand the answer

Hidradenitis suppurativa (HS) is a chronic, painful inflammatory skin condition affecting hair follicles and sweat glands, primarily in skin folds (axillae, groin, inframammary, perineal). It is characterized by recurrent nodules, abscesses, and tunnels (sinus tracts) that can cause significant pain, scarring, and impaired quality of life. HS affects approximately 1–4% of the population, with prevalence 3x higher in women and peak onset in the 20s–30s. Obesity and HS are strongly linked through multiple mechanisms: mechanical friction in skin folds, hyperandrogenism (common in obesity and PCOS), and systemic inflammation from visceral adiposity — particularly TNF-α and IL-17, which are central to HS pathophysiology. Patients with obesity have 3–4x higher HS prevalence and more severe disease course.

Emerging evidence suggests GLP-1 medications may benefit HS patients, particularly those with obesity. Mechanisms: (1) Weight loss reduces skin fold friction and skin occlusion — a primary mechanical trigger of HS lesions; (2) Reduction of visceral fat decreases systemic TNF-α and IL-17 — the inflammatory cytokines that drive HS; (3) Improvement in insulin resistance and hyperandrogenism — both worsen HS; (4) Direct GLP-1 anti-inflammatory effects on immune cells. Case series and retrospective analyses (2023–2025) have shown HS severity score (IHS4) reductions in obese patients on semaglutide or tirzepatide. No randomized controlled trial specifically in HS has been completed as of April 2026, but trials are in early design phase.

Published case series and retrospective data (limited in size, typically 20–100 patients) show: meaningful reduction in HS lesion count and severity scores in patients achieving 10–20% weight loss; some patients who previously required biologic therapy (adalimumab, secukinumab) were able to reduce biologic frequency or dose; improvement in Hurley stage (HS severity classification) in a subset of patients. The caveat: these are early-stage observational reports. The degree of improvement appears correlated with weight loss magnitude — patients losing 15%+ body weight show greater HS improvement than those losing <10%. HS in patients with BMI <30 (non-obese HS) is less likely to respond to GLP-1 since the obesity-inflammation mechanism is less operative.

No — GLP-1 medications should not replace established HS-specific treatments. Current standard of care for moderate-to-severe HS: adalimumab (Humira, FDA-approved for HS), secukinumab (FDA-approved for HS 2023), bimekizumab (approved 2024), antibiotics (clindamycin + rifampicin), and surgical drainage/excision. GLP-1's role in HS is as an adjunct that addresses the underlying metabolic driver — obesity — rather than a direct anti-inflammatory targeting HS-specific pathways. In clinical practice, obese HS patients may experience meaningful disease improvement as a secondary benefit of GLP-1 treatment initiated for obesity or metabolic indications. Dermatologists managing HS in obese patients should be aware of this effect.

Based on case reports and series, HS improvement with GLP-1 appears to follow the trajectory of weight loss: initial improvement in lesion frequency and severity typically observed after 10–15% weight loss (often months 3–6 of treatment); more significant improvement after 15–20% loss (months 6–12); most improvement is seen at stable goal weight (12+ months). HS is not an acute condition — improvement is gradual and correlates with sustained metabolic change rather than any direct drug effect. Patients should not expect immediate HS improvement at the start of GLP-1 treatment. Realistic timeline: 3–6 months for initial improvement signals; 12+ months for meaningful disease modification.

In-Depth Guide

GLP-1 Medications and Hidradenitis Suppurativa

HS is one of the most painful chronic skin conditions — and obesity is both a risk factor and a disease amplifier. GLP-1's anti-inflammatory and weight loss effects address exactly this intersection.

Why HS and Obesity Are Mechanistically Linked

Obesity Factor	Effect on HS
Visceral fat → TNF-α	TNF-α drives HS inflammation; TNF blockade (adalimumab) is HS treatment
Visceral fat → IL-17	IL-17 is a key HS inflammatory cytokine; IL-17 inhibitors approved for HS
Skin fold mechanical friction	Primary physical trigger of HS lesions in intertriginous areas
Hyperandrogenism	Worsens HS; common in obesity and PCOS
Insulin resistance	Promotes inflammatory signaling relevant to follicular occlusion

GLP-1 reduces visceral fat, improves insulin resistance, and decreases TNF-α and IL-17 — three of the top five HS pathophysiologic drivers.

HS Severity Classification (Hurley Staging)

Stage	Description	GLP-1 Likely Impact
Hurley I	Abscesses, no sinus tracts	Moderate improvement likely with weight loss
Hurley II	Sinus tracts, limited	Moderate improvement; biologic still indicated
Hurley III	Extensive tracts, diffuse	Surgery + biologic primary; GLP-1 as adjunct

Current Evidence Landscape

Evidence Type	Quality	Finding
Preclinical/mechanism	Strong	TNF-α, IL-17 reduction consistent with GLP-1 anti-inflammatory effects
Case reports	Moderate	Individual patients with significant HS improvement
Retrospective series	Limited	Positive signals; 20–100 patients; HS severity reduction
RCT in HS	None completed	Trials in design phase (as of April 2026)

Verdict: biologically plausible and observationally supported; awaiting RCT confirmation.

Management Approach for HS Patients Considering GLP-1

Step	Action
1	Ensure HS is being adequately treated by a dermatologist (standard of care first)
2	Evaluate GLP-1 candidacy on metabolic grounds (BMI, comorbidities)
3	Initiate GLP-1 for metabolic indication; inform dermatologist
4	Monitor HS severity scores (IHS4) at 3, 6, 12 months
5	Assess whether biologic dose/frequency can be modified as HS improves
6	Resistance training + skin fold hygiene as adjuncts to weight loss

GLP-1 Psoriasis Skin Conditions FAQ — GLP-1 and other inflammatory skin conditions
GLP-1 Inflammation FAQ — systemic anti-inflammatory effects of GLP-1
GLP-1 PCOS FAQ — PCOS, hyperandrogenism, and HS overlap
GLP-1 Weight Loss Expectations FAQ — timeline for meaningful weight loss

More GLP-1 FAQs

Explore other common questions about GLP-1 medications

Ready to Find Your Provider?

Take our quiz to get personalized provider recommendations based on your needs.

Find Your Match Compare Medications

GLP-1 Medications and Hidradenitis Suppurativa: Inflammation, Obesity, and Emerging Evidence

Quick Answers

In-Depth Guide

GLP-1 Medications and Hidradenitis Suppurativa

Why HS and Obesity Are Mechanistically Linked

HS Severity Classification (Hurley Staging)

Current Evidence Landscape

Management Approach for HS Patients Considering GLP-1

Related Resources

More GLP-1 FAQs

Compounded vs Brand-Name GLP-1 FAQ: Safety, Legality, and Key Differences

GLP-1 Medications and Addiction: Alcohol, Nicotine, and Opioid Use Disorder Research

GLP-1 Medications and ADHD: Dopamine Overlap, Stimulant Interactions, and Appetite Effects

GLP-1 and Alcohol: Can You Drink on Semaglutide or Tirzepatide?

GLP-1 Medications and Appetite Suppression: When It's Too Much

GLP-1 Medications and Athletic Performance: What Athletes and Active Patients Need to Know

GLP-1 vs Bariatric Surgery: Efficacy, Risks, Cost, and Who Should Choose Which

GLP-1 Medications and Birth Control: What You Need to Know

Body Recomposition on GLP-1: Losing Fat While Preserving Muscle

Cagrisema: The GLP-1 + Amylin Combination That May Surpass Tirzepatide

GLP-1 Medications and Cardiovascular Risk: Beyond the SELECT Trial

GLP-1 Medications for Adolescents: FDA Approval, Safety, and What Parents Need to Know

GLP-1 Medications and Brain Health: Cognition, Dementia Risk, and Neurological Effects

Compounding Pharmacies for GLP-1 Medications: 503A vs 503B, Safety, and Legal Status

Compounded GLP-1 Status April 2026: What's Legal, What's Not, and What Changed

GLP-1 Medications and Constipation: Causes and Relief

Is GLP-1 Worth the Cost? Cost-Effectiveness Explained

GLP-1 Cost & Insurance FAQ: What You'll Actually Pay for Semaglutide, Tirzepatide & More

GLP-1 Medications and Alcohol Cravings: What the Research Shows

Can You Get Semaglutide at CVS or Walgreens? GLP-1 Pharmacy FAQ

GLP-1 Medications and Dental Health: Dry Mouth, 'Ozempic Mouth,' and Oral Care

GLP-1 for Diabetes vs Weight Loss: Key Differences Explained

What to Eat (and Avoid) on Semaglutide — Diet FAQ

GLP-1 Dosing Schedule: When and How to Take Your Medication

GLP-1 Medication Drug Interactions: What to Watch For

GLP-1 Eligibility & Access FAQ: Do You Qualify for Semaglutide or Tirzepatide?

Can I Get a GLP-1 Prescription? BMI and Eligibility FAQ

Exercise on GLP-1 Medications: What to Do, When to Start, and How Much

GLP-1 Medications and Fatty Liver Disease (MASH/NAFLD): What to Know

First Week on GLP-1: What to Expect (Day by Day)

Food Noise and GLP-1 Medications: What It Is and Why It Goes Quiet

GLP-1 Medications for PCOS: Benefits, Evidence, and What to Expect

GLP-1 for Specific Conditions: PCOS, Type 2 Diabetes, Metabolic Syndrome & More

GLP-1 Medications and Gallbladder: Gallstone Risk FAQ

GLP-1 Medications and Gout: Uric Acid, Flares, and What to Expect

GLP-1 Medications and the Gut Microbiome: What the Research Shows

Does Semaglutide Cause Hair Loss? GLP-1 and Hair Loss FAQ

Headaches on GLP-1 Medications: Causes, Duration, and What Helps

GLP-1 Medications and Heart Disease: Benefits and Considerations

GLP-1 Medications and Heart Failure: STEP-HFpEF Results and What They Mean

GLP-1 Medications and Hypoglycemia: Who Is at Risk and What to Do

GLP-1 Medications and Systemic Inflammation: Beyond Weight Loss

GLP-1 Injection Sites: Where to Inject, How to Rotate, and What to Avoid

How to Inject Semaglutide: Step-by-Step Guide and FAQ

GLP-1 Insurance Denial: How to Appeal and Get Coverage

GLP-1 Prior Authorization: How to Get Your Insurance to Cover Ozempic or Wegovy

GLP-1 Medications and Joint Pain: What Weight Loss Does to Arthritis and Joints

GLP-1 Medications and Kidney Disease: What Patients Need to Know

Lab Tests Before and During GLP-1 Medication Treatment

GLP-1 Long-Term Safety: What We Know After 5+ Years of Data

GLP-1 Maintenance Dose: What Happens After You Reach Your Goal

GLP-1 Medications and Male Fertility: Sperm Quality, Testosterone, and What Men Should Know

GLP-1 Medication Storage: Temperature, Cold Chain, and What to Do If Your Pen Gets Warm

GLP-1 Medications Compared: Semaglutide vs Tirzepatide vs Liraglutide vs Orforglipron

GLP-1 Medications and Testosterone in Men: What the Evidence Shows

GLP-1 Medications During Menopause and Perimenopause: What Changes

GLP-1 Medications and Mental Health: Mood, Depression, and Anxiety

GLP-1 Medications and Metabolic Syndrome: Addressing All Five Criteria

GLP-1 Medications and Muscle Loss: What the Research Shows

GLP-1 Nausea: How to Manage It and When It Goes Away

GLP-1 Injections and Needle Phobia: How to Manage Fear and What Alternatives Exist

GLP-1 Non-Responders: Why Some People Don't Lose Weight and What to Do

GLP-1 and Obesity as a Disease: Why It's Not About Willpower

GLP-1 Medications for Adults Over 65: Benefits, Risks, and Special Considerations

Orforglipron: The First True Oral GLP-1 Pill Without Special Handling

GLP-1 Medications and Pancreatitis: Risk FAQ

GLP-1 Patient Advocacy Guide: Getting Your Prescription, Fighting Denials, and Talking to Your Doctor

GLP-1 Pen vs Vial: Brand-Name vs Compounded Delivery Compared

GLP-1 Weight Loss Plateau: Why It Happens and What To Do

GLP-1 Medications During Pregnancy and Breastfeeding: What You Need to Know